title: [Dynamics of antipirin test at patients with alcoholic liver disease on the background of metadoksin drug receiving].
abstract: OBJECTIVE
  To study the effect of the drug metadoxin on drug-metabolizing liver function in patients with liver lesions alcoholic etiology (ALD).
  
  
  METHODS
  36 patients with ALD, of which 16 patients were diagnosed with hepatitis, while 20 - with the liver cirrhosis. All the patients underwent biochemical blood analysis and the study of drug-metabolizing liver function according to the pharmacokinetics of antipyrine in saliva before and after treatment with metadoxin. Metadoxin was administered at a dose of 500 mg once a day for 28 days. Concentrations of antipyrine in saliva samples were determined by HPLC. RESULTS. It was shown that of 36 patients examined in the 28-patients with ALD (group 2) there was a significant decrease in activity of liver enzymes according to the test with antipyrine (T1/2 = 28.7 +/- 3.4, CL = 17,9 +/- 5.2; p < 0,01 vs normal), whereas in 8 patients (group 1) was noted the typical for alcohol inductive influence on the activity of liver monooxygenases (T1/2 = 7.8 +/- 1.5, CL = 39.1 +/- 6.8; p < 0,05 vs normal). As a result of the 28-day therapy with metadoxin was a normalization of the pharmacokinetic parameters of AP in Gr. 1 (12.6 +/- 1.8; p < 0.05; NS vs normal) and a significant improvement of it in patients of Gr. 2 (17.9 +/- 5.2, vs N, p <0.05). Biochemical markers of ALD (AST/ALT, GGT, ALP) also demonstrated a positive dynamics in patients of both study groups. Correlation analysis of changes in CL and GGT (r1) and changes in AST/ALT and T1/2 (r2) showed a fairly high degree of correlation between these parameters (r1 = 0.58, r2 = 0.65).
  
  
  CONCLUSIONS
  The results showed marked improvement of drug-metabolizing liver function according to the test with antipyrine in patients with ALD after treatment with metadoxin.
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Sil'vestrova
authors.forename: S Iu
authors.initials: SIu
authors.lastname: Fedotova
authors.forename: T F
authors.initials: TF
authors.lastname: Drozdov
authors.forename: A V
authors.initials: AV
authors.lastname: Petrakov
mesh_terms: D000328:Adult; D000427:Alcohol Deterrents / Q000008:administration & dosage*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000983:Antipyrine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008099:Liver / Q000378:metabolism; D008108:Liver Diseases, Alcoholic / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D006899:Mixed Function Oxygenases / Q000097:blood; D011736:Pyridoxine / Q000008:administration & dosage*; D011761:Pyrrolidonecarboxylic Acid / Q000008:administration & dosage*; D012463:Saliva / Q000378:metabolism
chemical_list: D000427:Alcohol Deterrents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004338:Drug Combinations; D006899:Mixed Function Oxygenases; C037845:metadoxine; D011736:Pyridoxine; D011761:Pyrrolidonecarboxylic Acid; D000983:Antipyrine